Summary:
Tralokinumab monotherapy for moderate to severe atopic dermatitis.
Qualified Participants Must:
• Be greater than or equal to 18 years old
•
AD for at least 1 year
•
Inadequate response to topical tx within 1 year
•
BSA greater than or equal to 1
•
IGA greater than or equal to 3
•
EASI greater than or equal to 12
Qualified Participants May Receive:
IL-13
68+ weeks (possible extension) of treatment
3:1 300 mg vs placebo for 16 weeks
After week 16-re-randomized 2:2:1 300 mg Q2, 300mg Q4 or placebo